Tiapride

Coma, CNS depression, phaeochromocytoma, prolactin dependent tumours, bone marrow suppression.

CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, paralytic ileus, prostatic hypertrophy, blood dyscrasias. Elderly.

Parkinsonian symptoms, drowsiness, agitation, insomnia, convulsions, dizziness, nasal congestion, antimuscurinic symptoms (e.g. dry mouth, constipation, blurred vision, difficulty with micturition and mydriasis), ECG changes, cardiac arrhythmias, orthostatic hypotension, photosensitisation, corneal and lens opacities. Delirium, nightmare, depression, inhibition of ejaculation, impotence, priapism, hypersensitivity reactions.
Potentially Fatal: Blood dyscrasias, neuroleptic malignant syndrome.

Increased risk of neuroleptic malignant syndrome with benzodiazepines. Increased risk of CNS depression with other CNS depressants e.g. general anaesthetics, hypnotics, anxiolytics and opioids. Increased antimuscarinic side effects with TCAs and antiparkinsonian drugs. Antagonised effects of dopaminergic drugs e.g. bromocriptine. Increased risk of QT interval prolongation with drugs that may prolong QT interval.

Description:
Mechanism of Action: Tiapride is an atypical neuroleptic agent with selective dopamine D₂-receptor antagonist activity and has general properties similar to sulpiride. It is unlikely to cause catalepsy and sedation and is used in the management of behaviour disorders and to treat dyskinesias.
Pharmacokinetics:
Absorption: Rapidly absorbed from GI tract. Peak plasma concentrations:1-2 hr.
Distribution: Distributed into breast milk
Excretion: Excreted largely unchanged in the urine. Plasma half-life : 3-4 hr.

Antipsychotics